Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 16, Issue 21, 2010, Pages 2604-2608

  Dubinsky, Marla Cindy ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti saccharomyces cerevisiae antibody; Crohn's disease; Fibrostenosing; Inflammatory bowel disease; Internal penetrating; Perinuclear anti neutrophil antibody; Pouchitis; Ulcerative colitis

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CALGRANULIN; CYCLOSPORIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUTROPHIL CYTOPLASMIC ANTIBODY; OROSOMUCOID; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; HUMAN; IMMUNE RESPONSE; PREDICTION; PROGNOSIS; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; ULCERATIVE COLITIS;

EID: 77953490394     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i21.2604     Document Type: Article

References (50)

1. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Büschenfelde KH. T cell specifcity and cross reactivity towards enterobacteria, bacteroides, bifdobacterium, and antigens from resident intestinal fora in humans. Gut 1999; 44: 812-818
2. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15: 293-299
3. Eggena M, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon LK, Braun J. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun 2000; 14: 83-97
4. Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, Targan SR, Braun J. Identification of a novel my-cobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immuno-globulin A from patients with Crohn's disease. Infect Immun 1999; 67: 6510-6517
5. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998; 18: 153-160
6. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J. Colonic bacteria express an ulcer-ative colitis pANCA-related protein epitope. Infect Immun 2000; 68: 1542-1548
7. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-829
8. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Pou-lain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791
9. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for in-fammatory bowel disease. J Pediatr 1999; 134: 447-452
10. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shana-han F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590-1596
11. Proujansky R, Fawcett PT, Gibney KM, Treem WR, Hyams JS. Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 17: 193-197
12. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994; 125: 707-711
13. Oberstadt K, Schaedel W, Weber M, Classen M, Deusch K. P-ANCA as a differential diagnostic marker in inflammatory bowel disease. Adv Exp Med Biol 1995; 371B: 1313-1316
14. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Antibodies against laminaribioside and chitobio-side are novel serologic markers in Crohn's disease. Gastroen-terology 2006; 131: 366-378
15. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123: 689-699
16. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papa-dakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 fagellin defne a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028
17. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47: 487-496
18. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccha-romyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-1122
19. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papada-kis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-424
20. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99: 2376-2384
21. Xue S, Stempak JM, Elkadri AA, Greenberg GR, Walters TD, Griffiths AM, Steinhart H, Silverberg MS. Serological markers are associated with severity of disease and need for surgery in IBD patients. Gastroenterology 2006; 130: S1303
22. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in in-fammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403
23. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008; 103: 665-681
24. Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 139-146
25. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliaus-kas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, Rotter JI, Markowitz J, Hyams J. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6: 1105-1111
26. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serologi-cal markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006; 101: 645-652
27. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinu-clear antineutrophil cytoplasmic antibodies in patients with Crohn's disease defne a clinical subgroup. Gastroenterology 1996; 110: 1810-1819
28. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaien-nie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001; 49: 671-677
29. Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas E, Mei L, Papadakis KA, Rotter JI, Landers C, Targan S. Both preop-erative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients infuence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6: 561-568
30. Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasil-iauskas EA, Papadakis KA, Dubinsky M, Landers C, Rotter JI, Targan SR. Family history and serology predictCrohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008; 51: 100-108
31. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798
32. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171-177
33. Fagerberg UL, Lööf L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003; 37: 468-472
34. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal infammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22
35. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368
36. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gas-troenterol 2008; 103: 2007-2014
37. Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, Algaba A, López P, López-Palacios N, Calvo M, González-Lama Y, Carneros JA, Velasco M, Maté J. Fecal calprotectin and lactoferrin for the prediction of infam-matory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-1198
38. Pepys MB, Druguet M, Klass HJ, Dash AC, Mirjah DD, Petrie A. Immunological studies in inflammatory bowel disease. Ciba Found Symp 1977; 283-304
39. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ul-cerative colitis. Gut 1986; 27: 809-813
40. Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-519
41. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14-19
42. Russell AI, Cunninghame Graham DS, Shepherd C, Rober-ton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Wal-port MJ, Vyse TJ. Polymorphism at the C-reactive protein locus infuences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-147
43. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, For-nage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77
44. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
45. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
46. Danesh J, Wheeler JG, Hirschfeld GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397
47. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737
48. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pal-lone F. The clinical signifcance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401-405
49. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Mary JY. Biological markers of short term relapse in Crohn"s disease (CD). Gastroenterology 2001; 20 suppl: A53
50. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ul-cerative colitis. Gut 1996; 38: 905-910